AMOSENE Drug Patent Profile
✉ Email this page to a colleague
When do Amosene patents expire, and what generic alternatives are available?
Amosene is a drug marketed by Ferndale Labs and is included in one NDA.
The generic ingredient in AMOSENE is meprobamate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the meprobamate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Amosene
A generic version of AMOSENE was approved as meprobamate by INVAGEN PHARMS on February 27th, 2008.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AMOSENE?
- What are the global sales for AMOSENE?
- What is Average Wholesale Price for AMOSENE?
Summary for AMOSENE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 33 |
| Patent Applications: | 5,715 |
| DailyMed Link: | AMOSENE at DailyMed |
US Patents and Regulatory Information for AMOSENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferndale Labs | AMOSENE | meprobamate | TABLET;ORAL | 084030-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
